Dr. Boccia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6410 Rockledge Dr
Suite 660
Bethesda, MD 20817Phone+1 301-571-0019Fax+1 301-571-0988
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1980 - 1981
- University of Minnesota Medical School
Certifications & Licensure
- CA State Medical License 1980 - Present
- MD State Medical License 1983 - 2026
- DC State Medical License 2002 - 2024
- NJ State Medical License 2015 - 2019
- MN State Medical License 1978 - 1986
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
- A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
- A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome Start of enrollment: 2004 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 516 citationsAvelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Luc Dirix, István Takács, Guy Jerusalem, Petros Nikolinakos, Hendrik Tobias Arkenau
Breast Cancer Research and Treatment. 2018-10-23 - 292 citationsRomiplostim or standard of care in patients with immune thrombocytopenia.David J. Kuter, Mathias J. Rummel, Ralph V. Boccia, B. Gail Macik, Ingrid Pabinger
The New England Journal of Medicine. 2010-11-10 - 77 citationsPhase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour
Cancer. 2017-03-15
Journal Articles
- Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVORRuben Niesvizky, David Siegel, Ralph Boccia, Blood
Abstracts/Posters
- Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective AnalysisRalph Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlle...Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- MediMergent Leverages Patient-Centric Real-World Data and Evidence Platform to Capture the Voice of the Patient in National Cancer TrialMarch 29th, 2023
- Fostamatinib More Effective Earlier in Treatment for Immune ThrombocytopeniaDecember 1st, 2020
- VerdePharmHealth and Altopa Enter into Exclusive Partnership Agreement for Patient-Centric CBD FormulationsSeptember 15th, 2020
- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: